Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients
| العنوان: | Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients |
|---|---|
| المؤلفون: | Olaf M. Dekkers, Gerlof D. Valk, Wouter T Zandee, M. R. Vriens, Wouter W. de Herder, Bas Havekes, Mirthe J Klein Haneveld, Annenienke C van de Ven, Peter H. Bisschop, Carolina R.C. Pieterman, Madeleine L. Drent, Annemarie A Verrijn Stuart, Mark J C van Treijen, Rachel S van Leeuwaarde |
| المساهمون: | Internal Medicine, Internal medicine, Amsterdam Neuroscience - Mood, Anxiety, Psychosis, Stress & Sleep, Amsterdam Gastroenterology Endocrinology Metabolism, Interne Geneeskunde, MUMC+: MA Endocrinologie (9), RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health, Endocrinology, AMS - Ageing & Vitality, AMS - Musculoskeletal Health |
| المصدر: | Journal of Clinical Endocrinology and Metabolism, 106, 3515-3525 Journal of Clinical Endocrinology and Metabolism, 106(12), 3515-3525. Endocrine Society Journal of Clinical Endocrinology and Metabolism, 106(12), 3515-3525. ENDOCRINE SOC Journal of Clinical Endocrinology and Metabolism, 106(12), 3515-3525. The Endocrine Society Journal of Clinical Endocrinology & Metabolism, 106(12), 3515-3525. Oxford University Press Journal of Clinical Endocrinology and Metabolism, 106, 12, pp. 3515-3525 Journal of clinical endocrinology and metabolism, 106(12), 3515-3525. The Endocrine Society Klein Haneveld, M J, van Treijen, M J C, Pieterman, C R C, Dekkers, O M, van de Ven, A, de Herder, W W, Zandee, W T, Drent, M L, Bisschop, P H, Havekes, B, Vriens, M R, Verrijn Stuart, A A, Valk, G D & van Leeuwaarde, R S 2021, ' Initiating Pancreatic Neuroendocrine Tumor (pNET) Screening in Young MEN1 Patients : Results from the DutchMEN Study Group ', Journal of Clinical Endocrinology and Metabolism, vol. 106, no. 12, pp. 3515-3525 . https://doi.org/10.1210/clinem/dgab569Test |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | Oncology, Male, Databases, Factual, Endocrinology, Diabetes and Metabolism, Neuroendocrine Tumors/diagnosis, Clinical Biochemistry, Disease, Biochemistry, multiple endocrine neoplasia type 1, Endocrinology, Medicine, Age of Onset, Multiple endocrine neoplasia, Child, Early Detection of Cancer, Netherlands, ENDOCRINE NEOPLASIA TYPE-1, education.field_of_study, INTERVAL-CENSORED-DATA, Middle Aged, Prognosis, Penetrance, age-related penetrance, Tumor Burden, Survival Rate, Neuroendocrine Tumors, Child, Preschool, Cohort, surveillance, Female, Rare cancers Radboud Institute for Health Sciences [Radboudumc 9], Adult, Diagnostic Imaging, medicine.medical_specialty, pancreatic NET, Adolescent, Population, Context (language use), Netherlands/epidemiology, Databases, Young Adult, SDG 3 - Good Health and Well-being, Internal medicine, Humans, MEN1, Pancreatic Neoplasms/diagnosis, education, Preschool, Survival analysis, Factual, Aged, Retrospective Studies, business.industry, Biochemistry (medical), medicine.disease, Pancreatic Neoplasms, Multiple Endocrine Neoplasia Type 1/physiopathology, Early Detection of Cancer/methods, business, Follow-Up Studies |
| الوصف: | ContextNonfunctioning pancreatic neuroendocrine tumors (NF-pNETs) are highly prevalent and constitute an important cause of mortality in patients with multiple endocrine neoplasia type 1 (MEN1). Still, the optimal age to initiate screening for pNETs is under debate.ObjectiveThe aim of this work is to assess the age of occurrence of clinically relevant NF-pNETs in young MEN1 patients.MethodsPancreatic imaging data of MEN1 patients were retrieved from the DutchMEN Study Group database. Interval-censored survival methods were used to describe age-related penetrance, compare survival curves, and develop a parametric model for estimating the risk of having clinically relevant NF-pNET at various ages. The primary objective was to assess age at occurrence of clinically relevant NF-pNET (size ≥ 20 mm or rapid growth); secondary objectives were the age at occurrence of NF-pNET of any size and pNET-associated metastasized disease.ResultsFive of 350 patients developed clinically relevant NF-pNETs before age 18 years, 2 of whom subsequently developed lymph node metastases. No differences in clinically relevant NF-pNET–free survival were found for sex, time frame, and type of MEN1 diagnosis or genotype. The estimated ages (median, 95% CI) at a 1%, 2.5%, and 5% risk of having developed a clinically relevant tumor are 9.5 (6.5-12.7), 13.5 (10.2-16.9), and 17.8 years (14.3-21.4), respectively.ConclusionAnalyses from this population-based cohort indicate that start of surveillance for NF-pNETs with pancreatic imaging at age 13 to 14 years is justified. The psychological and medical burden of screening at a young age should be considered. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 0021-972X |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2ce36b25c25d31e1a499d42dbc31157Test https://doi.org/10.1210/clinem/dgab569Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....b2ce36b25c25d31e1a499d42dbc31157 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 0021972X |
|---|